Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial

por Winston, Alan, and Puls, Rebekah, CSF Sub-study, group Encore
Publicado 2014

Assessing site performance in the Altair study, a multinational clinical trial

por Berthon-Jones, Nisha, Courtney-Vega, Kymme, Donaldson, Anna, Haskelberg, Hila, Emery, Sean, Puls, Rebekah
Publicado 2015

Changes in plasma lipidome following initiation of antiretroviral therapy

por Trevillyan, Janine M., Wong, Gerard, Puls, Rebekah, Petoumenos, Kathy, Emery, Sean, Mellett, Natalie A., Mundra, Piyushkumar A., Meikle, Peter J., Hoy, Jennifer F.
Publicado 2018

Differences in the Direction of Change of Cerebral Function Parameters Are Evident over Three Years in HIV-Infected Individuals Electively Commencing Initial cART

por Winston, Alan, Puls, Rebekah, Kerr, Stephen J., Duncombe, Chris, Li, Patrick, Gill, John M., Ramautarsing, Reshmie, Taylor-Robinson, Simon D., Emery, Sean, Cooper, David A.
Publicado 2015

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results o...

por Dickinson, Laura, Amin, Janaki, Else, Laura, Boffito, Marta, Egan, Deirdre, Owen, Andrew, Khoo, Saye, Back, David, Orrell, Catherine, Clarke, Amanda, Losso, Marcelo, Phanuphak, Praphan, Carey, Dianne, Cooper, David A., Emery, Sean, Puls, Rebekah
Publicado 2015